Table 1. Selected ongoing clinical trials in metastatic NSCLC exploring radiotherapy to the primary tumor and metastatic disease.

Clinical trial number	Study name	Patient characteristics
NCT03137771	Maintenance systemic therapy versus LCT Plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC): A Randomized Phase II/III Trial	NSCLC synchronous or metachronous oligometastatic (≤3 extracranial metastases)
NCT02417662	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A Randomized Phase III Trial (SARON)	NSCLC synchronous oligometastatic (≤3 metastases) EGFR/ALK negative or unknown mutational status
NCT03275597	Comprehensive SBRT to all sites of oligometastatic NSCLC combined with durvalumab (MEDI4736) and tremelimumab dual immune checkpoint inhibition	NSCLC synchronous oligometastatic ≤6 extracranial sites. EGFR/ALK negative
NCT03391869	Randomized Phase III trial of LCT after nivolumab and ipilimumab for immunotherapy-naive patients with metastatic non-small cell lung cancer (LONESTAR)	NSCLC poly- and oligometastatic EGFR/ALK-negative adenocarcinoma
NCT02893332	Tyrosine-kinase inhibitor with or without SBRT in newly diagnosed advanced staged lung adenocarcinoma	NSCLC synchronous or metachronous oligometastatic (≤5 metastases) with EGFR mutation

SBRT: Stereotactic body radiotherapy; LCT: Local consolidative therapy; NSCLC: Nonsmall cell lung cancer